TY - JOUR
T1 - European guidelines on microscopic colitis
T2 - United European Gastroenterology (UEG) and European Microscopic Colitis Group (EMCG) statements and recommendations
AU - Miehlke, Stephan
AU - Guagnozzi, Danila
AU - Zabana, Yamile
AU - Tontini, Gian E.
AU - Fiehn, Anne-Marie Kanstrup
AU - Wildt, Signe
AU - Bohr, Johan
AU - Bonderup, Ole
AU - Bouma, Gerd
AU - D'Amato, Mauro
AU - Engel, Peter Johan Heiberg
AU - Fernandez-Banares, Fernando
AU - Macaigne, Gilles
AU - Hjortswang, Henrik
AU - Hultgren-Hornquist, Elisabeth
AU - Koulaouzidis, Anastasios
AU - Kupcinskas, Jouzas
AU - Landolfi, Stefania
AU - Latella, Giovanni
AU - Lucendo, Alfredo
AU - Lyutakov, Ivan
AU - Madisch, Ahmed
AU - Magro, Fernando
AU - Marlicz, Wojciech
AU - Mihaly, Emese
AU - Munck, Lars Kristian
AU - Ostvik, Ann-Elisabeth
AU - Patai, Arpad
AU - Penchev, Plamen
AU - Skonieczna-Zydecka, Karolina
AU - Verhaegh, Bas
AU - Munch, Andreas
N1 - Funding Information:
The steering committee (S. M., A. M?., D. G., Y. Z., G. E. T., A. M. K., S. W.) organised the working groups and designed the preliminary list of topics to be covered. All authors systematically reviewed the literature and drafted the statements and recommendations and provided Grading of Recommendations Assessment, Development and Evaluation evaluations. All authors and members of the consensus group voted on the statements and recommendations. The steering committee then drafted the initial manuscript, which was reviewed, revised and approved by all authors and members of the consensus group. Subsequently it was made available to all members for final comments prior to submission for publication. Collaborators: Nadine Steubesand and Franziska Dambon, Clinical Guideline Services, Kiel, Germany. These guidelines have been developed with reasonable care and with the best of knowledge available to the authors at the time of preparation. They are intended to assist healthcare professionals and allied healthcare professionals as an educational tool to provide information that may support them in providing care to patients. Patients or other community members using these guidelines shall do so only after consultation with a health professional and shall not mistake these guidelines as professional medical advice. These guidelines must not substitute seeking professional medical and health advice from a health professional. These guidelines may not apply to all situations and should be interpreted in the light of specific clinical situations and resource availability. It is up to every clinician to adapt these guidelines to local regulations and to each patient's individual circumstances and needs. The information in these guidelines shall not be relied upon as being complete, current or accurate, nor shall it be considered as inclusive of all proper treatments or methods of care or as a legal standard of care. United European Gastroenterology (UEG) makes no warranty, express or implied, in respect of these guidelines and cannot be held liable for any damages resulting from the application of these guidelines, in particular for any loss or damage (whether direct or indirect) resulting from a treatment based on the guidance given herein. UEG shall not be held liable to the utmost extent permissible according to the applicable laws for any content available on such external websites, which can be accessed by using the links included herein. These guidelines were developed with the support of a UEG Activity Grant. The European Microscopic Colitis Group administered all aspects of the meetings without other external funding sources.
Publisher Copyright:
© 2020 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.
PY - 2021/2
Y1 - 2021/2
N2 - Introduction Microscopic colitis is a chronic inflammatory bowel disease characterised by normal or almost normal endoscopic appearance of the colon, chronic watery, non-bloody diarrhoea and distinct histological abnormalities, which identify three histological subtypes, the collagenous colitis, the lymphocytic colitis and the incomplete microscopic colitis. With ongoing uncertainties and new developments in the clinical management of microscopic colitis, there is a need for evidence-based guidelines to improve the medical care of patients suffering from this disorder. Methods Guidelines were developed by members from the European Microscopic Colitis Group and United European Gastroenterology in accordance with the Appraisal of Guidelines for Research and Evaluation II instrument. Following a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the certainty of the evidence. Statements and recommendations were developed by working groups consisting of gastroenterologists, pathologists and basic scientists, and voted upon using the Delphi method. Results These guidelines provide information on epidemiology and risk factors of microscopic colitis, as well as evidence-based statements and recommendations on diagnostic criteria and treatment options, including oral budesonide, bile acid binders, immunomodulators and biologics. Recommendations on the clinical management of microscopic colitis are provided based on evidence, expert opinion and best clinical practice. Conclusion These guidelines may support clinicians worldwide to improve the clinical management of patients with microscopic colitis.
AB - Introduction Microscopic colitis is a chronic inflammatory bowel disease characterised by normal or almost normal endoscopic appearance of the colon, chronic watery, non-bloody diarrhoea and distinct histological abnormalities, which identify three histological subtypes, the collagenous colitis, the lymphocytic colitis and the incomplete microscopic colitis. With ongoing uncertainties and new developments in the clinical management of microscopic colitis, there is a need for evidence-based guidelines to improve the medical care of patients suffering from this disorder. Methods Guidelines were developed by members from the European Microscopic Colitis Group and United European Gastroenterology in accordance with the Appraisal of Guidelines for Research and Evaluation II instrument. Following a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the certainty of the evidence. Statements and recommendations were developed by working groups consisting of gastroenterologists, pathologists and basic scientists, and voted upon using the Delphi method. Results These guidelines provide information on epidemiology and risk factors of microscopic colitis, as well as evidence-based statements and recommendations on diagnostic criteria and treatment options, including oral budesonide, bile acid binders, immunomodulators and biologics. Recommendations on the clinical management of microscopic colitis are provided based on evidence, expert opinion and best clinical practice. Conclusion These guidelines may support clinicians worldwide to improve the clinical management of patients with microscopic colitis.
KW - Microscopic colitis
KW - inflammatory bowel disease
KW - diarrhoea
KW - budesonide
KW - PLACEBO-CONTROLLED TRIAL
KW - QUALITY-OF-LIFE
KW - NONSTEROIDAL ANTIINFLAMMATORY DRUGS
KW - SUBEPITHELIAL COLLAGEN TABLE
KW - IRRITABLE-BOWEL-SYNDROME
KW - PUMP INHIBITOR USE
KW - LYMPHOCYTIC-COLITIS
KW - DOUBLE-BLIND
KW - CHRONIC DIARRHEA
KW - RISK-FACTORS
U2 - 10.1177/2050640620951905
DO - 10.1177/2050640620951905
M3 - (Systematic) Review article
C2 - 32819215
SN - 2050-6406
VL - 9
SP - 13
EP - 37
JO - United European Gastroenterology Journal
JF - United European Gastroenterology Journal
IS - 1
M1 - 2050640620951905
ER -